Higher Versus Standard Dose of Amoxicillin-clavulanate in Pediatric PBB
Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Chronic wet cough is one of the most common symptoms of respiratory diseases in children.
Protracted bacterial bronchitis (protracted bacterial bronchitis, PBB) is the most common
cause of chronic wet cough in children. Potassium amoxicillin clavulanate is the recommended
drug for the treatment of PBB, but there is not enough evidence to date on the dose and
course of treatment. investigate the efficacy of different doses of amoxicillin clavulanate
sodium in the treatment of chronic bacterial bronchitis in children. The methods of this
study are summarized as following:
1. Screening cases of chronic wet cough in children aged 2 to 6 years old who came to our
hospital for treatment. Those diagnosed as PBB were included in this study, after
obtaining the written informed consent from their parents or guardians.
2. The enrolled patients were randomly divided into high-dose (90mg/kg/d) and standard dose
(60mg/kg/d) amoxicillin clavulanate potassium treatment group.
3. Medical history data of enrolled patients and daily cough score data were collected.
4. Assess the cough remission rate within two weeks and recurrence rate within 6 months in
both groups.
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University